Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses
- PMID: 35210622
- DOI: 10.1038/s41590-022-01130-4
Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses
Abstract
Host genetic and environmental factors including age, biological sex, diet, geographical location, microbiome composition and metabolites converge to influence innate and adaptive immune responses to vaccines. Failure to understand and account for these factors when investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine efficacy may impair the development of the next generation of vaccines. Most studies aimed at identifying mechanisms of vaccine-mediated immune protection have focused on adaptive immune responses. It is well established, however, that mobilization of the innate immune response is essential to the development of effective cellular and humoral immunity. A comprehensive understanding of the innate immune response and environmental factors that contribute to the development of broad and durable cellular and humoral immune responses to SARS-CoV-2 and other vaccines requires a holistic and unbiased approach. Along with optimization of the immunogen and vectors, the development of adjuvants based on our evolving understanding of how the innate immune system shapes vaccine responses will be essential. Defining the innate immune mechanisms underlying the establishment of long-lived plasma cells and memory T cells could lead to a universal vaccine for coronaviruses, a key biomedical priority.
© 2022. Springer Nature America, Inc.
Similar articles
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
-
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27. Cancer Cell. 2021. PMID: 34348121 Free PMC article. No abstract available.
-
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021. Front Immunol. 2021. PMID: 35003131 Free PMC article.
-
A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.Sci Adv. 2021 Feb 5;7(6):eabe5819. doi: 10.1126/sciadv.abe5819. Print 2021 Feb. Sci Adv. 2021. PMID: 33547083 Free PMC article.
-
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.Vaccine. 2021 Jan 8;39(2):197-201. doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24. Vaccine. 2021. PMID: 33279318 Free PMC article. Review.
Cited by
-
BNT162b2 Booster Dose Elicits a Robust Antibody Response in Subjects with Abdominal Obesity and Previous SARS-CoV-2 Infection.Vaccines (Basel). 2023 Nov 30;11(12):1796. doi: 10.3390/vaccines11121796. Vaccines (Basel). 2023. PMID: 38140200 Free PMC article.
-
Immune response in COVID-19: what is next?Cell Death Differ. 2022 Jun;29(6):1107-1122. doi: 10.1038/s41418-022-01015-x. Epub 2022 May 17. Cell Death Differ. 2022. PMID: 35581387 Free PMC article. Review.
-
The furin cleavage site is required for pathogenesis, but not transmission, of SARS-CoV-2.J Virol. 2025 Jul 22;99(7):e0046725. doi: 10.1128/jvi.00467-25. Epub 2025 Jun 10. J Virol. 2025. PMID: 40492735 Free PMC article.
-
Promising use of immune cell-derived exosomes in the treatment of SARS-CoV-2 infections.Clin Transl Med. 2022 Aug;12(8):e1026. doi: 10.1002/ctm2.1026. Clin Transl Med. 2022. PMID: 35988156 Free PMC article. Review.
-
Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital.Vaccines (Basel). 2022 Jun 27;10(7):1031. doi: 10.3390/vaccines10071031. Vaccines (Basel). 2022. PMID: 35891194 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- U19AI090023/U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER)
- 1U54CA260563/U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER)
- U19 AI128910/AI/NIAID NIH HHS/United States
- R56 AI147623/AI/NIAID NIH HHS/United States
- U19 AI057266/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous